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SPECIFIC AIMS
Diabetic distal symmetric sensorimotor polyneurop-
athy affects up to 60 –70% of patients with diabetes
mellitus in the U.S. The best-studied mechanisms of
diabetic neuropathy include increased aldose reduc-
tase (AR) activity, nonenzymatic glycation/glycooxi-
dation, activation of protein kinase C, and impaired
neurotrophic support. These mechanisms contribute
to enhanced oxidative stress resulting from increased
production of reactive oxygen species (ROS) and
insufficient up- or down-regulation of antioxidative
defense.
Increased formation of the potent oxidant per-
oxynitrite (the product of superoxide anion radical
reaction with nitric oxide) has been documented in
experimental and clinical diabetic neuropathy. Per-
oxynitrite causes nitration and nitrosylation of bi-
omolecules including proteins, lipids, and DNA. Ni-
trosative stress has been implicated in DNA single
strand breakage, followed by poly(ADP-ribose) poly-
merase (PARP) activation, in pathological conditions
associated with oxidative stress. The pathogenetic
role of reactive nitrogen species in diabetic neurop-
athy remains unexplored. This study was designed to
evaluate the role for nitrosative stress in early dia-
betic neuropathy in two animal models of Type 1
diabetes mellitus [streptozotocin (STZ)-diabetic mice
and diabetic NOD mice], using the potent peroxy-
nitrite decomposition catalyst FP15.
PRINCIPAL FINDINGS
1. FP15 corrects physiological abnormalities
characteristic for peripheral diabetic neuropathy
in two models of Type 1 diabetes mellitus
Experiments were performed in STZ-diabetic mice
and NOD-diabetic mice. In experiment 1, control
and STZ-diabetic mice were treated with or without
FP15 (5 mg kg-1 d-1, in drinking water) for 1 wk after
initial 8 wk without treatment. Sciatic nerve motor
and hind-limb digital sensory nerve conduction ve-
locities (MNCV and SNCV) were measured at the
beginning of the study (prior to induction of dia-
betes), at 8 wk time point (prior to FP15 treatment)
and at the end of the study. After completion of
nerve functional studies, the mice were killed and
both sciatic nerves removed for biochemical [phos-
phocreatine (PCr), creatine (Cr), glucose, sorbitol,
fructose] and immunohistochemical [nitrotyrosine
(NT), poly(ADP-ribose), and PARP-1] measure-
ments. MNCV and SNCV were reduced in diabetic
mice 8 wk after induction of diabetes. They remained
reduced in the untreated group 9 wk after induction
of diabetes, whereas 1 wk FP15 treatment normalized
MNCV and essentially normalized SNCV (Fig. 1A).
FP15 treatment did not affect either MNCV or SNCV
in control mice. In experiment 2, diabetic NOD mice
were treated with either 1 or 3 mg kg-1 d-1 FP15 in
drinking water for 1 wk. FP15 dose-dependently
reversed increased tail-flick latency (a sign of hypoal-
gesia), and the effect of the higher dose was signifi-
cant as early as 3 days after the beginning of treat-
ment (Fig. 1B). FP15 treatment did not affect weight
gain or blood glucose concentrations in either model
of Type 1 diabetes. Body weights were similarly
reduced and blood glucose concentrations similarly
increased in untreated and FP15-treated diabetic
animals compared with corresponding nondiabetic
controls.
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2. FP15 treatment corrects energy failure, but does
not interfere with accumulation of glucose or sorbitol
pathway intermediates in the peripheral nerve in
streptozotocin-diabetic mice
PCr concentrations and PCr/Cr ratios were decreased
in peripheral nerve of streptozotocin-diabetic mice
compared with nondiabetic controls (Fig. 1C). Diabe-
tes-associated energy failure was corrected by FP15
treatment. Nerve glucose, sorbitol, and fructose con-
centrations were elevated in diabetic mice compared
with nondiabetic controls, and neither glucose nor
sorbitol pathway intermediate concentrations were af-
fected by FP15 treatment (Fig. 1D).
3. FP15 treatment counteracts nitrosative stress and
PARP activation without affecting PARP-1 abundance
in peripheral nerve of STZ-diabetic mice
Nitrotyrosine (NT) and poly(ADP-ribose) immunore-
activities were increased in the peripheral nerve of
STZ-diabetic mice, and diabetes-associated increase in
both variables was essentially corrected by FP15 treat-
ment (Fig. 2A, B, respectively). PARP-1 abundance in
the peripheral nerve was not affected by either diabetes
or FP15 treatment (Fig. 2C).
CONCLUSIONS AND SIGNIFICANCE
Nitrosative stress (peroxynitrite-induced injury) is an
important factor in numerous pathological conditions
associated with oxidative stress. Our results provide the
first evidence for the important role of peroxynitrite in
the pathogenesis of diabetic neuropathy in two models
of Type 1 (insulin-dependent) diabetes mellitus. Short
term treatment with a peroxynitrite decomposition
catalyst corrected motor and sensory nerve conduction
deficits as well as hypoalgesia characteristic for diabetic
neuropathy. FP15 appeared remarkably effective at
such low doses as 1, 3, and 5 mg kg-1 d-1. Thus, the
effective doses for the peroxynitrite decomposition
catalyst are, at least, 100-fold lower than the effective
doses for conventional, even the most potent (e.g.,
-lipoic acid) antioxidants. These findings suggest that
peroxynitrite is the most important oxidant involved in
the pathogenesis of diabetic neuropathy.
Another important finding in the present study is the
demonstration of the major role of nitrosative stress in
PARP activation in the diabetic peripheral nerve. PARP
activation is responsible for diabetes-associated down-
regulation (or, like in the peripheral nerve, insufficient
up-regulation) of the glycolytic enzyme glyceraldehyde
3-phosphate dehydrogenase, and activation of several
major pathways involved in the pathogenesis of diabetic
complications. PARP-1 is involved in transcriptional
regulation via direct binding or poly(ADP-ribosyl)ation
of transcription factors (NF-B, activator protein-1,
STAT-1, p53, and others). Our recent findings indicate
that PARP activation is a fundamental mechanism in
the pathogenesis of diabetic neuropathy, and that
motor and sensory nerve conduction deficits do not
develop in diabetic PARP-deficient (PARP/) mice.
Further studies are needed to identify pathways trig-
gered by nitrosative stress and subsequent PARP activa-
tion in the pathogenesis of diabetic complications.
Our findings provide further support to previous ob-
servations of our group and others indicating that from a
variety of metabolic parameters nerve energy state corre-
lates best with nerve conduction. Nerve PCr/Cr ratio, the
best marker of peripheral nerve energy state, was compro-
mised in streptozotocin-diabetic mice, and corrected by
short-term FP15 treatment. Thus, nitrosative stress is a
major contributor to energy failure in experimental dia-
betic neuropathy. The latter is consistent with the key role
Figure 1. A) Final sciatic motor nerve conduction velocities
and hind-limb digital sensory nerve conduction velocities in
control and STZ-diabetic mice treated with or without FP15.
n  12–14/group. C  control; D  diabetic; *P  0.05, **P
 0.01 vs. control group; #P  0.05, ##P  0.01 vs. untreated
diabetic group. B) Tail flick latencies in nondiabetic and
diabetic NOD mice treated FP15. n 5/group. **P 0.01 vs.
nondiabetic group; #P  0.05, ##P  0.01 vs. corresponding
values in NOD diabetic mice before treatments. C) Phospho-
creatine (PCr) concentrations and phosphocreatine/creatine
(PCr/Cr) ratios in the sciatic nerve of control and STZ-
diabetic mice treated with or without FP15. n  5–6/group.
**P 0.01 vs. control group; ##P 0.01 vs. untreated diabetic
group. D) Glucose and sorbitol pathway intermediate concen-
trations in control and STZ-diabetic mice treated with or
without FP15. n  6/group. **P  0.01 vs. control group; ##P
 0.01 vs. untreated diabetic group.
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for peroxynitrite and PARP activation in ATP or PCr
depletion and resulting energy failure in other patholog-
ical conditions associated with oxidative stress.
Our results contribute to a better understanding of
the relationship between increased AR activity and
oxidative stress/PARP activation in the pathogenesis of
diabetic complications, and in particular, diabetic neu-
ropathy. Numerous findings obtained with AR inhibi-
tors as well as AR-overexpressing mice indicate that
increased AR activity is one of the most important
mechanisms contributing to such complex phenome-
non as oxidative stress in tissue sites for diabetic com-
plications. Recently, one group has hypothesized that
oxidative stress and PARP activation precede and ac-
count for diabetes-associated increase in the sorbitol
pathway activity. In our study, FP15 counteracted nitro-
sative stress and PARP activation, but did not affect
glucose or sorbitol pathway intermediate accumulation
in diabetic peripheral nerve. The latter is consistent
with downstream localization of oxidative-nitrosative
stress and PARP activation consequent to increased AR
activity in the pathogenesis of diabetic complications.
Oxidative-nitrosative stress generated by increased AR
activity, nonenzymatic glycation/glycooxidation, activa-
tion of protein kinase C, mitochondrial respiratory
chain, extramitochondrial xanthine oxidase, and
NAD(P)H oxidase affects downstream signaling by mi-
togen-activated protein kinases, PARP, and other mech-
anisms, which in turn causes up-regulation of inducible
nitric oxide synthase, cyclooxygenase-2, endothelin-1,
inflammatory genes (secondary contributors to diabe-
tes-associated oxidative damage) (Fig. 3). The role of
these secondary mechanisms remains to be explored.
Our results provide the first evidence of the patho-
genetic role of reactive nitrogen species in periph-
eral diabetic neuropathy in two experimental mod-
els of Type 1 insulin-dependent diabetes. The
findings justify development of pharmacological
agents counteracting peroxynitrite formation and
promoting peroxynitrite decomposition and their
further study in animal and cell culture models of
diabetic neuropathy and other chronic complica-
tions of diabetes.
Figure 2. Representative microphotographs of immunohisto-
chemical staining of nitrotyrosine (A), poly(ADP-ribose) (B)
and poly(ADP-ribose) polymerase-1 (C) in the sciatic nerve of
control and streptozotocin-diabetic mice treated with or
without FP15. n  5–6/group. 400.
Figure 3. Interactions among oxidative-nitrosative stress and
other mechanisms implicated in the pathogenesis of periph-
eral diabetic neuropathy.
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